Toro-Salinas A H, Fort N, Torrella J R, Pagès T, Javierre C, Viscor G
Departament de Fisiologia i Immunologia, Universitat de Barcelona, Barcelona, Spain.
Physiological Sciences II, University of Barcelona, L'Hospitalet, Spain.
Int J Sports Med. 2016 Sep;37(10):785-91. doi: 10.1055/s-0035-1559774. Epub 2016 Jul 14.
The increase in pulmonary arterial pressure (PAP) due to hypoxic pulmonary vasoconstriction (HPV) could be a limiting factor for physical performance during hypoxic exposure. Sildenafil has been shown to reduce PAP in situations of moderate or severe hypoxia, and consequently its role as an ergogenic aid and even a possible doping substance must be considered. We performed a double-blind crossover study to determine the effects of sildenafil on cardiovascular, respiratory and metabolic parameters in normoxia and during acute exposure to hypobaric hypoxia (4 000 m) at rest and during maximal and submaximal (60% VO2 max) exercise tests. One hour before testing started, sildenafil (100 mg) or a placebo was orally administered to 11 volunteers. In normoxic conditions, sildenafil did not affect performance. Similarly, no significant differences were found in cardiovascular and respiratory parameters in hypoxic conditions at rest or during exercise. The use of sildenafil to improve physical performance in non-acclimatized subjects is not supported by our data.
由于低氧性肺血管收缩（HPV）导致的肺动脉压（PAP）升高可能是低氧暴露期间身体机能的限制因素。已表明西地那非可降低中度或重度低氧情况下的PAP，因此必须考虑其作为一种促力辅助剂甚至可能作为一种兴奋剂的作用。我们进行了一项双盲交叉研究，以确定西地那非在常氧以及在静息状态、最大运动和次最大运动（60%最大摄氧量）测试期间急性暴露于低压低氧（4000米）时对心血管、呼吸和代谢参数的影响。在测试开始前一小时，对11名志愿者口服西地那非（100毫克）或安慰剂。在常氧条件下，西地那非不影响运动表现。同样，在低氧条件下静息或运动期间，心血管和呼吸参数也未发现显著差异。我们的数据不支持使用西地那非来改善未适应环境的受试者的身体机能。
